Synonyms: Compound 1 [WO2022109595] | example F91 [WO2013033070]
Compound class:
Synthetic organic
Comment: The structure for labuxtinib was obtained from proposed INN list 129 (August 2023) where it is described as a tyrosine kinase inhibitor and antineoplastic agent. Patent information suggests that it is a c-KIT inhibitor [1-2]. It is likely that labuxtinib is Third Harmonic Bio's next-generation KIT inhibitor THB335. Development of their previous KIT inhibitor, THB001, was discontinued in late 2022 when hepatotoxicity was observed in a phase 1b study.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
A KIT inhibitor that is proposed for potential to treat mast cell-mediated inflammatory diseases. |